The company blamed its Q2 content slate and price increases for the subscriber miss.Technologyread more
Corporate earnings forecasts for the second quarter were lowered so much that companies are easily beating them.Market Insiderread more
The central bank is not normally in the business of easing into an economy that is showing few signs of a recession, generally holding fire until more pronounced signs of a...The Fedread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt. And growth is entirely dependent on Netflix's...Technologyread more
Prosecutors in Masschusetts have dropped a criminal case against actor Kevin Spacey, who had been accused of groping an 18-year-old man.Entertainmentread more
Yes, Netflix is losing "The Office" and "Friends" in the next two years. But that may not be a bad thing for the streaming company.Entertainmentread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
Trade negotiations between the world's two largest economies are stuck at a standstill, the Wall Street Journal reported Wednesday.Marketsread more
House Speaker Nancy Pelosi says she wants her chamber to vote on a debt ceiling and budget deal by July 26.Politicsread more
Philips has acquired a start-up that texts you about your poop. That's Medumo, a Boston-based company, which works with hospitals to guide their patients through common...Technologyread more
A U.S. jury on Tuesday found Bayer AG's glyphosate-based weed killer caused a man's non-Hodgkin's lymphoma in a bellwether trial that may help determine the course of hundreds of similar cases.
The finding by the unanimous jury in San Francisco federal court clears the way for that same jury to determine if Bayer unit Monsanto is liable and must pay damages to California resident Edwin Hardeman in a second trial phase.
Bayer in a statement on Tuesday said it was disappointed with the jury's initial decision.
"We are confident the evidence in phase two will show that Monsanto's conduct has been appropriate and the company should not be liable for Mr. Hardeman's cancer," the company said.
The case was only the second of some 11,200 Roundup lawsuits to go to trial in the United States. Another California man was awarded $289 million in August after a state court jury found Roundup caused his cancer, sending Bayer shares plunging at the time. That award was later reduced to $78 million and is on appeal.
Hardeman's case is expected to help determine the range of damages and define settlement options for more than 760 Roundup cases consolidated in the federal court in San Francisco.
Bayer denies allegations that Roundup, or glyphosate, cause cancer. It says decades of studies and regulatory evaluations, primarily of real-world human exposure data, have shown the weed killer to be safe for human use.
After five days of deliberations over scientific evidence presented during the trial, the jury on Tuesday found Roundup, one of the world's most widely-used weed killers, to be a "substantial factor" in causing Hardeman's cancer.
During the first phase, Hardeman's lawyers were not allowed to present evidence allegedly showing the company's efforts to influence scientists, regulators and the public about the safety of its products. They will be able to present that evidence in the second phase.
Hardeman's lawyers, Aimee Wagstaff and Jennifer Moore, said they look forward to presenting that evidence to the jury to hold Monsanto accountable.
"Now we can focus on the evidence that Monsanto has not taken a responsible, objective approach to the safety of Roundup," they said in a statement.